EMA Authorised: Xeplion (paliperidone palmitate) — Janssen-Cilag International N.V.

View source ↗

Summary

EMA authorises Xeplion (paliperidone palmitate) for schizophrenia, with Janssen-Cilag International N.V. as the MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Xeplion (paliperidone palmitate)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia. MAH: Janssen-Cilag International N.V.. Decision date: 19/07/2024